ASX-Dividend-Report-Banner

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

October 02, 2023 07:24 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Image source: Kalkine Media

SHENZHEN, China, Oct. 2, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co., Ltd. (hereinafter referred to as "SIBIONICS") will unveil its flagship product, the SIBIONICS GS1 Continuous Glucose Monitoring System (hereinafter referred to as "SIBIONICS GS1 CGM"), while also sharing its wealth of expertise and cutting-edge glucose monitoring technology with the global community.

SIBIONICS at the European Association for the Study of Diabetes (EASD)
SIBIONICS at the European Association for the Study of Diabetes (EASD)

Established in 2015, SIBIONICS is a high-tech firm specializing in the integration of implantable medical hardware technology and artificial intelligence algorithms. With its exceptional product quality and a user-centric service philosophy, SIBIONICS CGM captured an impressive market share, reaching nearly 20% within its inaugural year of launch in China, making it the leading domestically produced CGM. SIBIONICS GS1 CGM is the world's second CGM product to adopt second-generation sensor technology, offering calibration-free and scan-free features, as well as 14 days of real-time continuous monitoring. It stands out for its ease of use, accurate glucose levels measure, and comprehensive connectivity in various scenarios. The product is on the verge of obtaining CE certification from the European Union, promising a more scientifical and personalized approach to diabetes management for global users.

Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management. Powered by SIBIONICS CGM technology, the KS1 stands as the world's pioneer in combining sensor and transmitter functions, offering continuous real-time monitoring ketone levels up to 14 days.

What sets KS1 apart is its ability to calculate real-time fat-burning rates based on ketone levels, helping those with weight management goals assess their optimal fat-burning state. It is an innovative and groundbreaking product that completely revolutionizes the application of CKM in daily life, achieving the visualization and intelligence of the management process, making CKM even more significant in metabolic management.

As an innovative high-tech company that combines medical artificial intelligence technology with innovative medical products, SIBIONICS is expanding its portfolio to include more innovative medical products with data connectivity attributes, such as CLM, multi-functional sensor systems, capsule endoscopy systems, and insulin pump closed-loop systems. We sincerely invite experts, doctors, and patients to explore our products and exchange experiences.

SIBIONICS GS1: https://www.sibionicscgm.com/

SiBio KS1: https://www.sibiosensor.com/

Contact: zy.zhang@sibionics.com 

SIBIO CKM
SIBIO CKM

SIBIONICS CGM
SIBIONICS CGM


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.